Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Hyaluronidase Stories

2014-04-08 08:32:31

Additional preclinical data highlights the pharmacologic properties of PEGPH20 SAN DIEGO, April 8, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the American Association for Cancer Research (AACR) annual meeting being held in San Diego. The first presentation includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of...

2014-03-19 23:32:13

Several clients from other offices have come to Dr. Weiner to remove lumps, asymmetries, and swelling from HA dermal fillers and Dr. Weiner removes these undesired results with hyaluronidase injections. Sometimes, the improvements can be seen within minutes, but it can take up to 24 hours to see the full result, and possibly a second treatment is needed. Destin, FL (PRWEB) March 19, 2014 Hyaluronic Acid dermal fillers are the most popular fillers used worldwide. In the United States,...

2013-09-12 08:32:21

SAN DIEGO, Sept. 12, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer will be presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in Amsterdam. Additional data, including progression free and overall survival by hyaluronan (HA) status, will be...

2013-08-01 08:34:00

SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that following discussions with the Center for Biologics Evaluation and Research (CBER) division of the U.S. Food and Drug Administration, ViroPharma will be discontinuing their Phase 2 study of subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) with recombinant human hyaluronidase (rHuPH20). The discontinuation of the study is a precaution related to the emergence of an unexpected...

2013-06-12 08:21:57

DUBLIN, June 12, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/b3pqm4/hyaluronidase) has announced the addition of the "Hyaluronidase (CAS 37326-33-3) Market Research Report 2013" [http://www.researchandmarkets.com/research/b3pqm4/hyaluronidase ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Hyaluronidase (CAS 37326-33-3) Market Research Report 2013 presents comprehensive data on...

2013-03-22 08:25:02

LONDON, March 22, 2013 /PRNewswire/ -- Baxter International Inc. (NYSE: BAX) and Halozyme Therapeutics, Inc., (NASDAQ: HALO) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) has granted a Positive Opinion to Baxter for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. The product is a combination of human normal immunoglobulin (IGSC,...

2012-12-21 08:23:09

SAN DIEGO, Dec. 21, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc. (NYSE: PFE) for the purpose of developing and commercializing products combining proprietary Pfizer biologics with Halozyme's Enhanze(TM) technology. Enhanze is Halozyme's proprietary drug delivery platform and is based on the Company's patented recombinant human hyaluronidase enzyme (rHuPH20). (Logo:...

2012-11-08 16:28:17

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended September 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) "We are pleased with the clinical data from the subcutaneous MabThera (rituximab) trials which should enable filing of the marketing application in Europe later this year," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "With potential...

2012-08-01 10:26:30

SAN DIEGO, Aug. 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Baxter's HyQ Biologics License Application (BLA). HyQ is an investigational product that includes plasma-derived Immune Globulin (IG) 10% and Halozyme's recombinant human hyaluronidase (rHuPH20) for subcutaneous administration in patients...

2012-06-01 02:24:30

SAN DIEGO, June 1, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the Company will present data from its diabetes studies for both multiple daily injections (MDI) and continuous subcutaneous insulin infusion (CSII) Ultrafast Insulin programs at the 72nd Scientific Sessions of the American Diabetes Association (ADA) being held in Philadelphia, PA from June 8 - 12. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) The annual...